CompletedNCT01052103

LY2140023 or placebo added to standard treatment for schizophrenia symptoms

About this title

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Garden Grove and 8 more locationsSee all locations and recruitment
Study phase: Phase 2

Study clarity

Study start dateJanuary 2010

Recruitment status: Completed
Enrollment listed in the registry: 167
Sponsor: Denovo Biopharma LLC
Sponsor type: Biotech company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States, Israel, Italy, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT01052103
Official title: Show the full official title
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care (SOC) Compared to Placebo With SOC in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia

Completed

Garden Grove, United States · Chicago, United States · Hoffman Estates, United States

6 more locations

FAQ

Who is behind this study?

The study sponsor is Denovo Biopharma LLC.

Did this study involve medication?

Yes. The study involved medication, including LY2140023, Placebo and Standard of Care.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.